Agios Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in billions USD

Scroll to see more
Agios Pharmaceuticals, Inc. income statement - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.050.040.030.010.000.200.120.09
Cost of Revenue0.010.310.000.000.260.000.000.00
Gross Profit0.05-0.270.020.010.000.200.120.09
Operating Expenses
Research & Development0.340.300.300.280.260.220.410.34
Selling, General & Administrative0.180.160.120.120.120.120.130.11
Operating Expenses0.520.160.420.400.380.340.540.46
Operating Income-0.47-0.43-0.39-0.39-0.38-0.34-0.43-0.36
Other Income/Expense
Interest Income0.000.050.030.010.000.010.000.02
Interest Expense0.000.000.000.000.000.000.000.00
Other Income/Expense0.060.01-0.010.140.02-0.06-0.030.00
Income
Income Before Tax-0.410.72-0.35-0.23-0.36-0.33-0.41-0.35
Income Tax Expense0.000.040.000.000.000.000.000.00
Net Income-0.410.67-0.35-0.231.60-0.33-0.41-0.35
Net Income - Continuous Operations-0.410.67-0.35-0.23-0.360.000.000.00
Net Income - Discontinued Operations0.000.000.000.001.960.000.000.00
EBITDA-0.47-0.42-0.33-0.38-0.37-0.33-0.40-0.34
EBIT0.00-0.43-0.35-0.39-0.38-0.34-0.41-0.35
Depreciation & Amortization0.000.010.010.010.010.010.010.00
Earnings Per Share
Basic EPS-7.0012.00-6.00-4.0027.00-5.00-7.00-6.00
Diluted EPS-7.0012.00-6.00-4.0027.00-5.00-7.00-6.00
Basic Shares Outstanding0.060.060.060.050.060.070.060.06
Diluted Shares Outstanding0.060.060.060.050.060.090.060.06